Although recent clinical and experimental observations indicate the existence of a mutual relationship between the nervous and the immune system, the molecular mechanisms by which the two systems interact are just beginning to be studied. Neuropeptides that belong to the tachykinin family, such as substance-P, neurokinin A, and neurokinin B, could play an important immunoregulatory role in vivo, based on the following observations: a) the presence of SP and NKA in the lymphoid organs; b) the existence of SP receptors on lymphocytes; and c) the in vitro immunomodulatory activity of SP and NKA. The major objective of this proposal is to determine whether SP and related neurokinins modulate the immune response through the regulation of cytokine expression. Preliminary results indicated that: a) SP induced the production of IL-2 in murine T cell lines and murine normal lymphocyte cell cultures in a dose-dependent and specific manner; b) SP induced de novo synthesis of IL-2; and c) SP induced the expression of IFNgamma in murine splenocytes, in the absence or presence of suboptimal doses of ConA. We propose to continue and expand the molecular analysis of the immunoregulatory activity of SP and related neurokinins by: a) investigating the molecular mechanisms, including transcriptional and posttranscriptional regulation, by which SP and NKA stimulate IL-2 and IFNgamma production in murine splenocytes and T cell lines; b) investigating the cellular target(s) for SP action within the normal lymphocyte/macrophage population, and the intercellular communications leading to IL-2 or IFNgamma production as a result of SP stimulation; c) studying the expression of SP receptors in murine T lymphocytes. The study of the molecular mechanisms by which neuropeptides regulate the expression of interleukins, and therefore affect the outcome of the immune response, will offer new insights in the immunomodulatory activity of the nervous system in normal and pathological conditions. This could lead to new ways of controlling and manipulating the activity of the immune system, which in turn could become significant for the development of new treatments for AIDS patients.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
1R01MH049079-01A1
Application #
3388559
Study Section
Psychobiological, Biological, and Neurosciences Subcommittee (MHAI)
Project Start
1993-03-01
Project End
1996-02-29
Budget Start
1993-03-01
Budget End
1994-02-28
Support Year
1
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Rutgers University
Department
Type
Schools of Arts and Sciences
DUNS #
130029205
City
Newark
State
NJ
Country
United States
Zip Code
07102
Wang, H Y; Jiang, X; Gozes, I et al. (1999) Vasoactive intestinal peptide inhibits cytokine production in T lymphocytes through cAMP-dependent and cAMP-independent mechanisms. Regul Pept 84:55-67
Xin, Z; Sun, L; Ganea, D (1997) Vasoactive intestinal peptide stimulates p59fyn kinase activity in murine thymocytes. Peptides 18:1151-9
Xin, Z; Jiang, X; Wang, H Y et al. (1997) Effect of vasoactive intestinal peptide (VIP) on cytokine production and expression of VIP receptors in thymocyte subsets. Regul Pept 72:41-54
McCormack, R J; Hart, R P; Ganea, D (1996) Expression of NK-1 receptor mRNA in murine T lymphocytes. Neuroimmunomodulation 3:35-46
Wang, H Y; Xin, Z; Tang, H et al. (1996) Vasoactive intestinal peptide inhibits IL-4 production in murine T cells by a post-transcriptional mechanism. J Immunol 156:3243-53
Johnson, M C; McCormack, R J; Delgado, M et al. (1996) Murine T-lymphocytes express vasoactive intestinal peptide receptor 1 (VIP-R1) mRNA. J Neuroimmunol 68:109-19
Martinez, C; Delgado, M; Gomariz, R P et al. (1996) Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide-38 inhibit IL-10 production in murine T lymphocytes. J Immunol 156:4128-36
Delgado, M; Martinez, C; Johnson, M C et al. (1996) Differential expression of vasoactive intestinal peptide receptors 1 and 2 (VIP-R1 and VIP-R2) mRNA in murine lymphocytes. J Neuroimmunol 68:27-38
Xin, Z; Tang, H; Ganea, D (1994) Vasoactive intestinal peptide inhibits interleukin (IL)-2 and IL-4 production in murine thymocytes activated via the TCR/CD3 complex. J Neuroimmunol 54:59-68
Sun, L; Ganea, D (1993) Vasoactive intestinal peptide inhibits interleukin (IL)-2 and IL-4 production through different molecular mechanisms in T cells activated via the T cell receptor/CD3 complex. J Neuroimmunol 48:59-69